Aerie Pharmaceuticals announced topline efficacy results from a double-masked, randomized, placebo-controlled study designed to evaluate the effect of Rhopressa ophthalmic solution 0.02% on aqueous humor dynamics in patients with open-angle glaucoma or ocular hypertension. This study is the first performed on glaucoma patients to confirm that it lowers intraocular pressure primarily through this mechanism. The primary endpoint of the study was the mean change from baseline in the mean diurnal outflow facility. In the study, Rhopressa produced a statistically significant increase in trabecular outflow facility of approximately 35% over baseline. This topline finding is consistent with the published results of a study of similar design in healthy volunteers in which Rhopressa was also shown to exert a statistically significant effect on trabecular outflow facility.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.